294
Views
7
CrossRef citations to date
0
Altmetric
Research Article

Safety and toxicological evaluation of a novel, water-soluble undenatured type II collagen

, , , &
Pages 491-499 | Received 31 Jan 2013, Accepted 26 Feb 2013, Published online: 20 Jun 2013

References

  • Ames BN, McCann J, Yamasaki E. (1977). Methods for the Salmonella mutagenicity test. In: Kilbey BJ, ed. Handbook of mutagenicity test procedures. Amsterdam: Elsevier, 1–17
  • Arthritis Foundation. Osteoarthritis: what is it? Available from: http://www.arthritis.org/disease-center.php?disease_id=32 [last accessed 16 April 2010]
  • Bagchi D, Moriyama H, Raychaudhuri SP, eds. (2011). Arthritis: pathophysiology, prevention and therapeutics. Boca Raton (FL): CRC Press/Taylor & Francis
  • Barnett ML, Combitchi D, Trentham DE. (1996). A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum 39:623–8
  • Barnett ML, Kremer JM, St Clair EW, et al. (1998). Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 41:290–7
  • Berenbaum F. (2008). New horizons and perspectives in the treatment of osteoarthritis. Arthritis Res Ther 10:S1
  • Bitton R. (2009). The economic burden of osteoarthritis. Am J Manag Care 15:S230–5
  • Clive D. (1983). Viable chromosomal mutations affecting the TK locus in L5178Y/TK+/− mouse lymphoma cells: the other half of the assay. Ann NY Acad Sci 407:253–7
  • Clive D, McCuen R, Spector JF, et al. (1983). Specific gene mutations in L5178Y cells in culture. Mutat Res 115:225–51
  • Clive D, Spector JF. (1975). Laboratory procedure for assessing specific locus mutations at the TK locus in cultured L5178Y mouse lymphoma cells. Mutat Res 31:17–29
  • Draize JH, Woodward G, Calvery HO. (1944). Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membrane. J Pharm Exp Ther 82:377–90
  • FDA. (1987). Good laboratory practices (GLP) for non-clinical laboratory studies. In Department of Health and Human Services. Washington, DC: US Food and Drug Administration, 297–310
  • Felson DT, Lawrence RC, Dieppe PA, et al. (2000). Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med 133:635–46
  • Gingerich DA, Strobel JD. (2003). Use of client-specific outcome measures to assess treatment effects in geriatric, arthritic dogs: controlled clinical evaluation of a nutraceutical. Vet Ther 4:56–66
  • Goggs R, Vaughan-Thomas A, Clegg PD, et al. (2005). Nutraceutical therapies for degenerative joint diseases: a critical review. Crit Rev Food Sci Nutr 45:145–64
  • Helmick CG, Felson DT, Lawrence RC, et al. (2008). Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 58:15–25
  • Hootman JM, Helmick CG. (2006). Projections of the US prevalence of arthritis and associated activity limitations. Arthritis Rheum 54:226–9
  • Kay JH, Calandra JC. (1962). Interpretation of eye irritation tests. J Soc Cos Chem 13:281–9
  • Lawrence RC, Felson DT, Helmick CG, et al. (2008). Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 58:26–35
  • Maron DM, Ames BN. (1983). Revised methods for the Salmonella mutagenicity test. Mutat Res 113:173–215
  • McCarthy G, O'Donovan J, Jones B, et al. (2007). Randomised double-blind, positive-controlled trial to assess the efficacy of glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis. Vet J 174:54–61
  • Mitchell AD, Auletta AE, Clive D, et al. (1997). The L5178Y/TK+/− mouse lymphoma specific gene and chromosomal mutation assay a phase III report of the U.S. Environmental Protection Agency Gene-Tox Program. Mutat Res 394:177–303
  • National Research Council. (2011). Guide for the care and use of laboratory animals. 8th ed. Washington, DC: National Research Council
  • OECD. (1998). OECD environmental health and safety publications. Paris: Committee, C. G. a. M. Principles of Good Laboratory Practice Organization for Economic Cooperation and Development
  • Sarzi-Puttini P, Cimmino MA, Scarpa R, et al. (2005). Osteoarthritis: an overview of the disease and its treatment strategies. Semin Arthritis Rheum 35:1–10
  • Sauvé F, Paradis M, Refsal KR, et al. (2003). Effects of oral administration of meloxicam, carprofen, and a nutraceutical on thyroid function in dogs with osteoarthritis. Can Vet J 44:474–9
  • The Mayo Clinic. Osteoarthritis: causes. Available from: http://www.mayoclinic.com/health/osteoarthritis/DS00019/DSECTION=causes [last accessed 9 Feb 2009]
  • Trentham DE. (1996). Evidence that type II collagen feeding can induce a durable therapeutic response in some patients with rheumatoid arthritis. Ann NY Acad Sci 778:306–14
  • Trentham DE, Dynesius-Trentham RA, Orav EJ, et al. (1993). Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261:1727–30
  • Trentham DE, Halpner AD, Trentham RA, et al. (2001). Use of undenatured type II collagen in the treatment of rheumatoid arthritis. Clin Pract Altern Med 2:254–9
  • Yoshinari O, Shiojima Y, Moriyama H. et al. (2013). Effects of water-soluble undenatured type II collagen on collagen-induced arthritic mice. J Med Food (communicated)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.